KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $1.6 billion.

  • Alnylam Pharmaceuticals' Total Current Liabilities rose 2742.89% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 2742.89%. This contributed to the annual value of $1.2 billion for FY2024, which is 2257.59% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Total Current Liabilities is $1.6 billion, which was up 2742.89% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Total Current Liabilities peaked at $1.6 billion during Q3 2025, and registered a low of $494.8 million during Q1 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Total Current Liabilities value was $788.6 million (recorded in 2023), while the average stood at $888.2 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Total Current Liabilities soared by 4605.61% in 2021 and then surged by 1037.86% in 2022.
  • Alnylam Pharmaceuticals' Total Current Liabilities (Quarter) stood at $695.7 million in 2021, then increased by 10.38% to $767.9 million in 2022, then rose by 26.03% to $967.8 million in 2023, then grew by 22.58% to $1.2 billion in 2024, then soared by 31.12% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.1 billion during Q1 2025.